Pheast Therapeutics

Home - Pheast

Pheast Therapeutics was founded in 2020, is headquartered in Redwood City, United States, lists 11–50 employees, and has $101.0M in recorded funding across 2 rounds.

Employees
11–50
Founded
2020
Business Model
B2B
Website
pheast.com
Total Funding
$101.0M
Last Round
$76.0M Series AApr 2022
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 3 investors for this company. The full record is or through the API.

About

Pheast Therapeutics is a clinical-stage immuno-oncology company developing macrophage checkpoint inhibitors to activate the innate immune system against cancer. Building on Stanford discoveries that CD24 is a dont-eat-me signal used by tumors, the company is advancing PHST001, an anti-CD24 antibody, in a Phase 1 study of advanced solid tumors. Pheast also uses a discovery platform to find additional macrophage-targeted immunotherapies and combination strategies with existing anti-cancer treatments. The company is led by the scientists who made the foundational discoveries and is backed by investors including Catalio Capital Management and ARCH Venture Partners.

Summary

Pheast Therapeutics is a Biotech company based in Redwood City, United States, founded in 2020. It lists 11–50 employees. It has raised $101.0M in total across 2 rounds, most recently a $76.0M Series A round in Apr 2022. Investors include ARCH Venture Partners, Catalio Capital Management and Alexandria Venture Investments.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AApr 2022
$76.0M

Sign up to see all 2 events

Funding: Series A. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Pheast Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/pheast-therapeutics"><img src="https://indexed.vc/api/badge/company/pheast-therapeutics" alt="Pheast Therapeutics on Indexed.vc" width="260" height="76" /></a>